C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
Spoke,
C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and…